{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:51:00Z","timestamp":1790700660638,"version":"4.1.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:00:00Z","timestamp":1490745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00702-017-1715-x","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T12:53:14Z","timestamp":1490791994000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The use of nonhuman primate models to understand processes in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"125","author":[{"given":"Javier","family":"Blesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Trigo-Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia L\u00f3pez-Gonz\u00e1lez","family":"del Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Obeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"1715_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JPD-150604","volume":"5","author":"D Aarsland","year":"2015","unstructured":"Aarsland D, Kramberger MG (2015) Neuropsychiatric symptoms in Parkinson\u2019s\u00a0disease. J Parkinsons Dis 5:659\u2013667. doi: 10.3233\/JPD-150604","journal-title":"J Parkinsons Dis"},{"key":"1715_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00702-012-0768-0","volume":"119","author":"K Adachi","year":"2012","unstructured":"Adachi K, Kobayashi M, Kawasaki T et al (2012) Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson\u2019s disease. J Neural Transm 119:933\u2013941. doi: 10.1007\/s00702-012-0768-0","journal-title":"J Neural Transm"},{"key":"1715_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cne.10689","volume":"461","author":"Y Ai","year":"2003","unstructured":"Ai Y, Markesbery W, Zhang Z et al (2003) Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461:250\u2013261. doi: 10.1002\/cne.10689","journal-title":"J Comp Neurol"},{"key":"1715_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1254\/jjp.67.117","volume":"67","author":"T Akai","year":"1995","unstructured":"Akai T, Ozawa M, Yamaguchi M et al (1995) Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn J Pharmacol 67:117\u2013124","journal-title":"Jpn J Pharmacol"},{"key":"1715_CR5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366\u2013375","journal-title":"Trends Neurosci"},{"key":"1715_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s007020050228","volume":"106","author":"H Almirall","year":"1999","unstructured":"Almirall H, Pigarev I, de la Calzada MD et al (1999) Nocturnal sleep structure and temperature slope in MPTP treated monkeys. J Neural Transm 106:1125\u20131134. doi: 10.1007\/s007020050228","journal-title":"J Neural Transm"},{"key":"1715_CR7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.870060404","volume":"6","author":"TZ Aziz","year":"1991","unstructured":"Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 6:288\u2013292","journal-title":"Mov Disord"},{"key":"1715_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jns.2016.12.060","volume":"373","author":"R Balestrino","year":"2017","unstructured":"Balestrino R, Martinez-Martin P (2017) Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson\u2019s disease. J Neurol Sci 373:173\u2013178. doi: 10.1016\/j.jns.2016.12.060","journal-title":"J Neurol Sci"},{"key":"1715_CR9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1523\/JNEUROSCI.2010-15.2016","volume":"36","author":"B Ballanger","year":"2016","unstructured":"Ballanger B, Beaudoin-Gobert M, Neumane S et al (2016) Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms. J Neurosci 36:1577\u20131589. doi: 10.1523\/JNEUROSCI.2010-15.2016","journal-title":"J Neurosci"},{"key":"1715_CR10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"PA Ballard","year":"1985","unstructured":"Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949\u2013956","journal-title":"Neurology"},{"key":"1715_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/exnr.2000.7408","volume":"164","author":"KS Bankiewicz","year":"2000","unstructured":"Bankiewicz KS, Eberling JL, Kohutnicka M et al (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2\u201314. doi: 10.1006\/exnr.2000.7408","journal-title":"Exp Neurol"},{"key":"1715_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","volume":"14","author":"KS Bankiewicz","year":"2006","unstructured":"Bankiewicz KS, Forsayeth J, Eberling JL et al (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14:564\u2013570. doi: 10.1016\/j.ymthe.2006.05.005","journal-title":"Mol Ther"},{"key":"1715_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11910-015-0571-z","volume":"15","author":"D Bannon","year":"2015","unstructured":"Bannon D, Landau AM, Doudet DJ (2015) How relevant are imaging findings in animal models of movement disorders to human disease? Curr Neurol Neurosci Rep 15:53. doi: 10.1007\/s11910-015-0571-z","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1715_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.expneurol.2009.07.019","volume":"219","author":"Q Barraud","year":"2009","unstructured":"Barraud Q, Lambrecq V, Forni C et al (2009) Sleep disorders in Parkinson\u2019s disease: the contribution of the MPTP non-human primate model. Exp Neurol 219:574\u2013582. doi: 10.1016\/j.expneurol.2009.07.019","journal-title":"Exp Neurol"},{"key":"1715_CR15","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1523\/JNEUROSCI.0181-14.2014","volume":"34","author":"H Belaid","year":"2014","unstructured":"Belaid H, Adrien J, Laffrat E et al (2014) Sleep disorders in Parkinsonian macaques: effects of l-Dopa treatment and pedunculopontine nucleus lesion. J Neurosci 34:9124\u20139133. doi: 10.1523\/JNEUROSCI.0181-14.2014","journal-title":"J Neurosci"},{"key":"1715_CR16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1460-9568.1993.tb00505.x","volume":"5","author":"A Benazzouz","year":"1993","unstructured":"Benazzouz A, Gross C, F\u00e9ger J et al (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5:382\u2013389","journal-title":"Eur J Neurosci"},{"key":"1715_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0166-2236(91)90179-X","volume":"14","author":"B Berger","year":"1991","unstructured":"Berger B, Gaspar P, Verney C (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 14:21\u201327","journal-title":"Trends Neurosci"},{"key":"1715_CR18","doi-asserted-by":"crossref","unstructured":"Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science (80) 249:1436\u20131438","DOI":"10.1126\/science.2402638"},{"key":"1715_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","volume":"72","author":"H Bergman","year":"1994","unstructured":"Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72:507\u2013520","journal-title":"J Neurophysiol"},{"key":"1715_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.25366","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E, Tronci E, Pioli EY et al (2013) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28:1088\u20131096. doi: 10.1002\/mds.25366","journal-title":"Mov Disord"},{"key":"1715_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/mds.25920","volume":"29","author":"E Bezard","year":"2014","unstructured":"Bezard E, Pioli EY, Li Q et al (2014) The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 29:1074\u20131079. doi: 10.1002\/mds.25920","journal-title":"Mov Disord"},{"key":"1715_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mds.870130507","volume":"13","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798\u2013802. doi: 10.1002\/mds.870130507","journal-title":"Mov Disord"},{"key":"1715_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fnana.2014.00155","volume":"8","author":"J Blesa","year":"2014","unstructured":"Blesa J, Przedborski S (2014) Parkinson\u2019s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155. doi: 10.3389\/fnana.2014.00155","journal-title":"Front Neuroanat"},{"key":"1715_CR24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.nbd.2010.03.006","volume":"38","author":"J Blesa","year":"2010","unstructured":"Blesa J, Juri C, Collantes M et al (2010) Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis 38:456\u2013463. doi: 10.1016\/j.nbd.2010.03.006","journal-title":"Neurobiol Dis"},{"key":"1715_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nbd.2012.05.018","volume":"48","author":"J Blesa","year":"2012","unstructured":"Blesa J, Pifl C, S\u00e1nchez-Gonz\u00e1lez MA et al (2012) The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol Dis 48:79\u201391. doi: 10.1016\/j.nbd.2012.05.018","journal-title":"Neurobiol Dis"},{"key":"1715_CR26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-199010000-00006","volume":"13","author":"S Boyce","year":"1990","unstructured":"Boyce S, Rupniak NM, Steventon MJ, Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by l-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448\u2013458","journal-title":"Clin Neuropharmacol"},{"key":"1715_CR27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U et al (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211","journal-title":"Neurobiol Aging"},{"key":"1715_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","volume":"36","author":"L Brichta","year":"2013","unstructured":"Brichta L, Greengard P, Flajolet M (2013) Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems. Trends Neurosci 36:543\u2013554. doi: 10.1016\/j.tins.2013.06.003","journal-title":"Trends Neurosci"},{"key":"1715_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01244987","volume":"76","author":"WJ Brooks","year":"1989","unstructured":"Brooks WJ, Jarvis MF, Wagner GC (1989) Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 76:1\u201312. doi: 10.1007\/BF01244987","journal-title":"J Neural Transm"},{"key":"1715_CR30","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns RS, Chiueh CC, Markey SP et al (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546\u20134550","journal-title":"Proc Natl Acad Sci USA"},{"key":"1715_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/srep00910","volume":"2","author":"M-H Canron","year":"2012","unstructured":"Canron M-H, Perret M, Vital A et al (2012) Age-dependent \u03b1-synuclein aggregation in the Microcebus murinus lemur primate. Sci Rep 2:910. doi: 10.1038\/srep00910","journal-title":"Sci Rep"},{"key":"1715_CR32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cne.900920303","volume":"92","author":"MB Carpenter","year":"1950","unstructured":"Carpenter MB, Whittier JR, Mettler FA (1950) Analysis of choreoid hyperkinesia in the Rhesus monkey; surgical and pharmacological analysis of hyperkinesia resulting from lesions in the subthalamic nucleus of Luys. J Comp Neurol 92:293\u2013331","journal-title":"J Comp Neurol"},{"key":"1715_CR33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2982.2008.01226.x","volume":"21","author":"T Chaumette","year":"2009","unstructured":"Chaumette T, Lebouvier T, Aubert P et al (2009) Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motil 21:215\u2013222","journal-title":"Neurogastroenterol Motil"},{"key":"1715_CR34","unstructured":"Chen JJ (2010) Parkinson\u2019s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 16:S87\u2013S93"},{"key":"1715_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-016-1654-y","author":"M Chen","year":"2016","unstructured":"Chen M, Liu J, Lu Y et al (2016) Age-dependent alpha-synuclein accumulation is correlated with elevation of mitochondrial TRPC3 in the brains of monkeys and mice. J Neural Transm. doi: 10.1007\/s00702-016-1654-y","journal-title":"J Neural Transm"},{"key":"1715_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","volume":"25","author":"Y Chu","year":"2007","unstructured":"Chu Y, Kordower JH (2007) Age-associated increases of \u03b1-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson\u2019s disease? Neurobiol Dis 25:134\u2013149. doi: 10.1016\/j.nbd.2006.08.021","journal-title":"Neurobiol Dis"},{"key":"1715_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nbd.2006.11.013","volume":"26","author":"TJ Collier","year":"2007","unstructured":"Collier TJ, Lipton J, Daley BF et al (2007) Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26:56\u201365. doi: 10.1016\/j.nbd.2006.11.013","journal-title":"Neurobiol Dis"},{"key":"1715_CR38","doi-asserted-by":"publisher","first-page":"a009431","DOI":"10.1101\/cshperspect.a009431","volume":"2","author":"PG Coune","year":"2012","unstructured":"Coune PG, Schneider BL, Aebischer P (2012) Parkinson\u2019s disease: gene therapies. Cold Spring Harb Perspect Med 2:a009431\u2013a009432. doi: 10.1101\/cshperspect.a009431","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1715_CR39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0028-3908(85)90070-X","volume":"24","author":"AR Crossman","year":"1985","unstructured":"Crossman AR, Mitchell IJ, Sambrook MA (1985) Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 24:587\u2013591","journal-title":"Neuropharmacology"},{"key":"1715_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fneur.2015.00146","volume":"6","author":"Alonso B Celis de","year":"2015","unstructured":"de Celis Alonso B, Hidalgo-Tob\u00f3n SS, Men\u00e9ndez-Gonz\u00e1lez M et al (2015) Magnetic resonance techniques applied to the diagnosis and treatment of Parkinson\u2019s disease. Front Neurol 6:146. doi: 10.3389\/fneur.2015.00146","journal-title":"Front Neurol"},{"key":"1715_CR41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281\u2013285","journal-title":"Trends Neurosci"},{"key":"1715_CR42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1152\/jn.1985.53.2.530","volume":"53","author":"MR DeLong","year":"1985","unstructured":"DeLong MR, Crutcher MD, Georgopoulos AP (1985) Primate globus pallidus and subthalamic nucleus: functional organization. J Neurophysiol 53:530\u2013543","journal-title":"J Neurophysiol"},{"key":"1715_CR43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355:896\u2013908. doi: 10.1056\/NEJMoa060281","journal-title":"N Engl J Med"},{"key":"1715_CR44","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","volume":"20","author":"T Paolo Di","year":"2014","unstructured":"Di Paolo T, Gr\u00e9goire L, Feuerbach D et al (2014) AQW051, a novel and selective nicotinic acetylcholine receptor \u03b17 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 20:1119\u20131123. doi: 10.1016\/j.parkreldis.2014.05.007","journal-title":"Parkinsonism Relat Disord"},{"key":"1715_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/0300985815622974","volume":"53","author":"ES Didier","year":"2016","unstructured":"Didier ES, MacLean AG, Mohan M et al (2016) Contributions of nonhuman primates to research on aging. Vet Pathol 53:277\u2013290. doi: 10.1177\/0300985815622974","journal-title":"Vet Pathol"},{"key":"1715_CR46","doi-asserted-by":"publisher","first-page":"15076","DOI":"10.1038\/srep15076","volume":"5","author":"ME Downs","year":"2015","unstructured":"Downs ME, Buch A, Karakatsani ME et al (2015) Blood\u2013brain barrier opening in behaving non-human primates via focused ultrasound with systemically administered microbubbles. Sci Rep 5:15076. doi: 10.1038\/srep15076","journal-title":"Sci Rep"},{"key":"1715_CR47","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/mds.23643","volume":"26","author":"G Du","year":"2011","unstructured":"Du G, Lewis MM, Styner M et al (2011) Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson\u2019s disease. Mov Disord 26:1627\u20131632. doi: 10.1002\/mds.23643","journal-title":"Mov Disord"},{"key":"1715_CR48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.124.3211.79","volume":"124","author":"GM Everett","year":"1956","unstructured":"Everett GM, Blockus LE, Shepperd IM (1956) Tremor induced by tremorine and its antagonism by anti-Parkinson drugs. Science 124:79","journal-title":"Science"},{"key":"1715_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jnc.13618","volume":"139","author":"BH Falkenburger","year":"2016","unstructured":"Falkenburger BH, Saridaki T, Dinter E (2016) Cellular models for Parkinson\u2019s disease. J Neurochem 139:121\u2013130. doi: 10.1111\/jnc.13618","journal-title":"J Neurochem"},{"key":"1715_CR50","doi-asserted-by":"publisher","first-page":"19559","DOI":"10.1073\/pnas.0706006104","volume":"104","author":"A Feigin","year":"2007","unstructured":"Feigin A, Kaplitt MG, Tang C et al (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson\u2019s disease. Proc Natl Acad Sci 104:19559\u201319564. doi: 10.1073\/pnas.0706006104","journal-title":"Proc Natl Acad Sci"},{"key":"1715_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","volume":"184","author":"SH Fox","year":"2010","unstructured":"Fox SH, Brotchie JM (2010) The MPTP-lesioned non-human primate models of Parkinson\u2019s disease. Past, present, and future. Prog Brain Res 184:133\u2013157. doi: 10.1016\/S0079-6123(10)84007-5","journal-title":"Prog Brain Res"},{"key":"1715_CR52","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","volume":"63","author":"SH Fox","year":"2006","unstructured":"Fox SH, Visanji NP, Johnston TH et al (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63:1343\u20131344. doi: 10.1001\/archneur.63.9.1343","journal-title":"Arch Neurol"},{"key":"1715_CR53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","volume":"37","author":"SH Fox","year":"2010","unstructured":"Fox SH, Visanji N, Reyes G et al (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson\u2019s disease. Can J Neurol Sci 37:86\u201395","journal-title":"Can J Neurol Sci"},{"key":"1715_CR54","doi-asserted-by":"publisher","unstructured":"George S, Brundin P (2017) Solving the conundrum of insoluble protein aggregates. Lancet Neurol 16(4):258\u2013259. doi: 10.1016\/S1474-4422(17)30045-5","DOI":"10.1016\/S1474-4422(17)30045-5"},{"key":"1715_CR55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589\u2013595. doi: 10.1038\/nm850","journal-title":"Nat Med"},{"key":"1715_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww230","author":"M Goedert","year":"2016","unstructured":"Goedert M, Masuda-Suzukake M, Falcon B (2016) Like prions: the propagation of aggregated tau and \u03b1-synuclein in neurodegeneration. Brain. doi: 10.1093\/brain\/aww230","journal-title":"Brain"},{"key":"1715_CR57","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","volume":"17","author":"L Gr\u00e9goire","year":"2011","unstructured":"Gr\u00e9goire L, Morin N, Ouattara B et al (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17:270\u2013276. doi: 10.1016\/j.parkreldis.2011.01.008","journal-title":"Parkinsonism Relat Disord"},{"key":"1715_CR58","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125","author":"R Grondin","year":"2002","unstructured":"Grondin R, Zhang Z, Yi A et al (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125:2191\u20132201","journal-title":"Brain"},{"key":"1715_CR59","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1523\/JNEUROSCI.23-05-01974.2003","volume":"23","author":"R Grondin","year":"2003","unstructured":"Grondin R, Cass WA, Zhang Z et al (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23:1974\u20131980","journal-title":"J Neurosci"},{"key":"1715_CR60","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.neurol.2015.07.011","volume":"171","author":"P Gubellini","year":"2015","unstructured":"Gubellini P, Kachidian P (2015) Animal models of Parkinson\u2019s disease: an updated overview. Rev Neurol (Paris) 171:750\u2013761. doi: 10.1016\/j.neurol.2015.07.011","journal-title":"Rev Neurol (Paris)"},{"key":"1715_CR201","unstructured":"Guridi J, Rodriguez-Oroz MC, Lozano AM, Moro E, Albanese A, Nuttin B, Gybels J, Ramos E, Obeso JA (2000) Targeting the basal ganglia for deep brain stimulation in Parkinson's disease. Neurology 55(6):S21\u2013S28"},{"key":"1715_CR61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.neucir.2016.02.006","volume":"27","author":"J Guridi","year":"2016","unstructured":"Guridi J, Marigil M, Becerra V, Parras O (2016) Neuroprotective subthalamotomy in Parkinson\u2019s disease. The role of magnetic resonance-guided focused ultrasound in early surgery. Neurocirugia (Astur) 27:285\u2013290. doi: 10.1016\/j.neucir.2016.02.006","journal-title":"Neurocirugia (Astur)"},{"key":"1715_CR62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng0298-155","volume":"18","author":"JG Hacia","year":"1998","unstructured":"Hacia JG, Makalowski W, Edgemon K et al (1998) Evolutionary sequence comparisons using high-density oligonucleotide arrays. Nat Genet 18:155\u2013158. doi: 10.1038\/ng0298-155","journal-title":"Nat Genet"},{"key":"1715_CR63","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.neuroscience.2015.05.041","volume":"300","author":"K Hikishima","year":"2015","unstructured":"Hikishima K, Ando K, Komaki Y et al (2015a) Voxel-based morphometry of the marmoset brain: in vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson\u2019s disease model. Neuroscience 300:585\u2013592. doi: 10.1016\/j.neuroscience.2015.05.041","journal-title":"Neuroscience"},{"key":"1715_CR64","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1148\/radiol.14140601","volume":"275","author":"K Hikishima","year":"2015","unstructured":"Hikishima K, Ando K, Yano R et al (2015b) Parkinson disease: diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Radiology 275:430\u2013437. doi: 10.1148\/radiol.14140601","journal-title":"Radiology"},{"key":"1715_CR65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/jpet.104.066191","volume":"310","author":"MP Hill","year":"2004","unstructured":"Hill MP, Ravenscroft P, Bezard E et al (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther 310:386\u2013394. doi: 10.1124\/jpet.104.066191","journal-title":"J Pharmacol Exp Ther"},{"key":"1715_CR66","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuropharm.2015.05.033","volume":"97","author":"P Huot","year":"2015","unstructured":"Huot P, Johnston TH, Fox SH et al (2015) The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology 97:306\u2013311. doi: 10.1016\/j.neuropharm.2015.05.033","journal-title":"Neuropharmacology"},{"key":"1715_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.nbd.2013.10.029","volume":"63","author":"C Hyacinthe","year":"2014","unstructured":"Hyacinthe C, Barraud Q, Tison F et al (2014) D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiol Dis 63:20\u201324. doi: 10.1016\/j.nbd.2013.10.029","journal-title":"Neurobiol Dis"},{"key":"1715_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsmc.2015.10.011","volume":"11","author":"A Iranzo","year":"2016","unstructured":"Iranzo A (2016) Sleep in neurodegenerative diseases. Sleep Med Clin 11:1\u201318. doi: 10.1016\/j.jsmc.2015.10.011","journal-title":"Sleep Med Clin"},{"key":"1715_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00702-013-1082-1","volume":"121","author":"MJ Jackson","year":"2014","unstructured":"Jackson MJ, Swart T, Pearce RKB, Jenner P (2014) Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. J Neural Transm 121:163\u2013169. doi: 10.1007\/s00702-013-1082-1","journal-title":"J Neural Transm"},{"key":"1715_CR70","doi-asserted-by":"publisher","unstructured":"Jarraya B, Boulet S, Scott Ralph G et al (2009) Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1:2ra4\u20132ra4. doi: 10.1126\/scitranslmed.3000130","DOI":"10.1126\/scitranslmed.3000130"},{"key":"1715_CR71","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","volume":"82","author":"JA Javitch","year":"1985","unstructured":"Javitch JA, D\u2019Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173\u20132177","journal-title":"Proc Natl Acad Sci USA"},{"key":"1715_CR72","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00702-015-1405-5","volume":"122","author":"KA Jellinger","year":"2015","unstructured":"Jellinger KA (2015) Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm 122:1429\u20131440. doi: 10.1007\/s00702-015-1405-5","journal-title":"J Neural Transm"},{"key":"1715_CR73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","volume":"50","author":"P Jenner","year":"1984","unstructured":"Jenner P, Rupniak NM, Rose S et al (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50:85\u201390","journal-title":"Neurosci Lett"},{"key":"1715_CR74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(99)00575-8","volume":"96","author":"D Joel","year":"2000","unstructured":"Joel D, Weiner I (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451\u2013474","journal-title":"Neuroscience"},{"key":"1715_CR75","doi-asserted-by":"crossref","unstructured":"Johnston TM, Fox SH (2014) Symptomatic models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia in non-human primates. In: Current topics in behavioral neurosciences, pp 221\u2013235","DOI":"10.1007\/7854_2014_352"},{"key":"1715_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2008.137","volume":"20","author":"LC Johnston","year":"2009","unstructured":"Johnston LC, Eberling J, Pivirotto P et al (2009) Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20:497\u2013510. doi: 10.1089\/hum.2008.137","journal-title":"Hum Gene Ther"},{"key":"1715_CR77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","volume":"73","author":"TH Johnston","year":"2013","unstructured":"Johnston TH, Huot P, Fox SH et al (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337\u2013347. doi: 10.1016\/j.neuropharm.2013.06.005","journal-title":"Neuropharmacology"},{"key":"1715_CR78","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. doi: 10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"1715_CR79","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369:2097\u20132105. doi: 10.1016\/S0140-6736(07)60982-9","journal-title":"Lancet"},{"key":"1715_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1678-y","author":"C Karachi","year":"2017","unstructured":"Karachi C, Francois C (2017) Role of the pedunculopontine nucleus in controlling gait and sleep in normal and parkinsonian monkeys. J Neural Transm. doi: 10.1007\/s00702-017-1678-y","journal-title":"J Neural Transm"},{"key":"1715_CR81","doi-asserted-by":"publisher","first-page":"e0166861","DOI":"10.1371\/journal.pone.0166861","volume":"11","author":"K Kimura","year":"2016","unstructured":"Kimura K, Inoue K, Kuroiwa Y et al (2016) Propagated but topologically distributed forebrain neurons expressing alpha-synuclein in aged macaques. PLoS One 11:e0166861. doi: 10.1371\/journal.pone.0166861","journal-title":"PLoS One"},{"key":"1715_CR82","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1073\/pnas.0536383100","volume":"100","author":"D Kirik","year":"2003","unstructured":"Kirik D, Annett LE, Burger C et al (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson\u2019s disease. Proc Natl Acad Sci USA 100:2884\u20132889. doi: 10.1073\/pnas.0536383100","journal-title":"Proc Natl Acad Sci USA"},{"key":"1715_CR83","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mds.25859","volume":"29","author":"WKD Ko","year":"2014","unstructured":"Ko WKD, Pioli E, Li Q et al (2014) Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease. Mov Disord 29:772\u2013779. doi: 10.1002\/mds.25859","journal-title":"Mov Disord"},{"key":"1715_CR84","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/mds.23867","volume":"26","author":"C Kobylecki","year":"2011","unstructured":"Kobylecki C, Hill MP, Crossman AR, Ravenscroft P (2011) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson\u2019s disease. Mov Disord 26:2354\u20132363. doi: 10.1002\/mds.23867","journal-title":"Mov Disord"},{"key":"1715_CR85","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/mds.23631","volume":"26","author":"JB Koprich","year":"2011","unstructured":"Koprich JB, Fox SH, Johnston TH et al (2011) The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson\u2019s disease. Mov Disord 26:1225\u20131233. doi: 10.1002\/mds.23631","journal-title":"Mov Disord"},{"key":"1715_CR86","doi-asserted-by":"publisher","first-page":"e0167235","DOI":"10.1371\/journal.pone.0167235","volume":"11","author":"JB Koprich","year":"2016","unstructured":"Koprich JB, Johnston TH, Reyes G et al (2016) Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson\u2019s disease: optimization of AAV1\/2 delivery parameters to drive sustained expression of alpha synuclein and dopaminergic degeneration in macaque. PLoS One 11:e0167235. doi: 10.1371\/journal.pone.0167235","journal-title":"PLoS One"},{"key":"1715_CR87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","volume":"46","author":"JH Kordower","year":"1999","unstructured":"Kordower JH, Palfi S, Chen EY et al (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson\u2019s disease. Ann Neurol 46:419\u2013424","journal-title":"Ann Neurol"},{"key":"1715_CR88","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"JH Kordower","year":"2000","unstructured":"Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease. Science 290:767\u2013773","journal-title":"Science"},{"key":"1715_CR89","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B et al (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706\u2013715. doi: 10.1002\/ana.21032","journal-title":"Ann Neurol"},{"key":"1715_CR90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mds.26890","volume":"32","author":"P Krack","year":"2017","unstructured":"Krack P, Martinez-Fernandez R, del Alamo M, Obeso JA (2017) Current applications and limitations of surgical treatments for movement disorders. Mov Disord 32:36\u201352. doi: 10.1002\/mds.26890","journal-title":"Mov Disord"},{"key":"1715_CR91","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s007020170018","volume":"108","author":"A Kupsch","year":"2001","unstructured":"Kupsch A, Sautter J, G\u00f6tz ME et al (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985\u20131009. doi: 10.1007\/s007020170018","journal-title":"J Neural Transm"},{"key":"1715_CR92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000098965","volume":"58","author":"LV Laitinen","year":"1992","unstructured":"Laitinen LV, Bergenheim AT, Hariz MI (1992) Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact Funct Neurosurg 58:14\u201321","journal-title":"Stereotact Funct Neurosurg"},{"key":"1715_CR93","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","volume":"292","author":"JW Langston","year":"1984","unstructured":"Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292:390\u2013394","journal-title":"Brain Res"},{"key":"1715_CR94","doi-asserted-by":"publisher","unstructured":"Lee JM, Derkinderen P, Kordower JH et al (2017) The search for a peripheral biopsy indicator of \u03b1-synuclein pathology for Parkinson disease. J Neuropathol Exp Neurol nlw103. doi: 10.1093\/jnen\/nlw103","DOI":"10.1093\/jnen\/nlw103"},{"key":"1715_CR95","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373:2055\u20132066. doi: 10.1016\/S0140-6736(09)60492-X","journal-title":"Lancet"},{"key":"1715_CR96","doi-asserted-by":"publisher","unstructured":"Leinenga G, Gotz J (2015) Scanning ultrasound removes amyloid- and restores memory in an Alzheimer\u2019s disease mouse model. Sci Transl Med 7:278ra33\u2013278ra33. doi: 10.1126\/scitranslmed.aaa2512","DOI":"10.1126\/scitranslmed.aaa2512"},{"key":"1715_CR97","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrneurol.2016.13","volume":"12","author":"G Leinenga","year":"2016","unstructured":"Leinenga G, Langton C, Nisbet R, G\u00f6tz J (2016) Ultrasound treatment of neurological diseases\u2014current and emerging applications. Nat Rev Neurol 12:161\u2013174. doi: 10.1038\/nrneurol.2016.13","journal-title":"Nat Rev Neurol"},{"key":"1715_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.025","author":"A Lenka","year":"2016","unstructured":"Lenka A, Hegde S, Arumugham SS, Pal PK (2016a) Pattern of cognitive impairment in patients with Parkinson\u2019s disease and psychosis: a critical review. Parkinsonism Relat Disord. doi: 10.1016\/j.parkreldis.2016.12.025","journal-title":"Parkinsonism Relat Disord"},{"key":"1715_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.11.018","volume":"22","author":"A Lenka","year":"2016","unstructured":"Lenka A, Hegde S, Jhunjhunwala KR, Pal PK (2016b) Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson\u2019s disease: a review. Parkinsonism Relat Disord 22:1\u20138. doi: 10.1016\/j.parkreldis.2015.11.018","journal-title":"Parkinsonism Relat Disord"},{"key":"1715_CR100","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0000000000002509","volume":"86","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Fahn S (2016) Levodopa therapy for Parkinson disease: table. Neurology 86:S3\u2013S12. doi: 10.1212\/WNL.0000000000002509","journal-title":"Neurology"},{"key":"1715_CR101","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA et al (2011) AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309\u2013319. doi: 10.1016\/S1474-4422(11)70039-4","journal-title":"Lancet Neurol"},{"key":"1715_CR102","doi-asserted-by":"crossref","unstructured":"Limousin P, Pollak P, Benazzouz A et al (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (London, England) 345:91\u201395","DOI":"10.1016\/S0140-6736(95)90062-4"},{"key":"1715_CR103","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mds.870100523","volume":"10","author":"P Limousin","year":"1995","unstructured":"Limousin P, Pollak P, Benazzouz A et al (1995b) Bilateral subthalamic nucleus stimulation for severe Parkinson\u2019s disease. Mov Disord 10:672\u2013674. doi: 10.1002\/mds.870100523","journal-title":"Mov Disord"},{"key":"1715_CR104","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/jcbfm.2011.166","volume":"32","author":"Y Ma","year":"2012","unstructured":"Ma Y, Peng S, Spetsieris PG et al (2012) Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab 32:633\u2013642. doi: 10.1038\/jcbfm.2011.166","journal-title":"J Cereb Blood Flow Metab"},{"key":"1715_CR105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol 7:400\u2013408","journal-title":"Lancet Neurol"},{"key":"1715_CR106","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks","year":"2010","unstructured":"Marks WJ, Bartus RT, Siffert J et al (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164\u20131172. doi: 10.1016\/S1474-4422(10)70254-4","journal-title":"Lancet Neurol"},{"key":"1715_CR107","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/brain\/50.3-4.637","volume":"50","author":"JP Martin","year":"1927","unstructured":"Martin JP (1927) Hemichorea resulting from a local lesion of the brain (the syndrome of the body of luys). Brain 50:637\u2013649. doi: 10.1093\/brain\/50.3-4.637","journal-title":"Brain"},{"key":"1715_CR108","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Schmitt E, Martinez-Martin P, Krack P (2016) The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Mov Disord 31:1080\u20131094. doi: 10.1002\/mds.26731","journal-title":"Mov Disord"},{"key":"1715_CR109","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-12-0128","volume":"72","author":"N McDannold","year":"2012","unstructured":"McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS (2012) Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652\u20133663. doi: 10.1158\/0008-5472.CAN-12-0128","journal-title":"Cancer Res"},{"key":"1715_CR110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-1-4684-5347-8_29","volume-title":"The basal ganglia II","author":"WC Miller","year":"1987","unstructured":"Miller WC, De Long MR (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A (eds) The basal ganglia II. Plenum Press, New York, pp 415\u2013427"},{"key":"1715_CR111","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0169-328X(00)00288-6","volume":"87","author":"GM Miller","year":"2001","unstructured":"Miller GM, Yatin SM, De La Garza R et al (2001) Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res Mol Brain Res 87:124\u2013143","journal-title":"Brain Res Mol Brain Res"},{"key":"1715_CR112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0306-4522(89)90120-6","volume":"32","author":"IJ Mitchell","year":"1989","unstructured":"Mitchell IJ, Clarke CE, Boyce S et al (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32:213\u2013226","journal-title":"Neuroscience"},{"key":"1715_CR113","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle MS, Webber PJ, Tse T et al (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32:1602\u20131611. doi: 10.1523\/JNEUROSCI.5601-11.2012","journal-title":"J Neurosci"},{"key":"1715_CR114","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.neuropharm.2015.08.002","volume":"99","author":"N Morin","year":"2015","unstructured":"Morin N, Morissette M, Gr\u00e9goire L et al (2015a) Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications. Neuropharmacology 99:356\u2013368. doi: 10.1016\/j.neuropharm.2015.08.002","journal-title":"Neuropharmacology"},{"key":"1715_CR115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pnpbp.2014.07.006","volume":"56","author":"N Morin","year":"2015","unstructured":"Morin N, Morissette M, Gr\u00e9goire L, Di Paolo T (2015b) Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys. Prog Neuro-Psychopharmacol Biol Psychiatry 56:27\u201338. doi: 10.1016\/j.pnpbp.2014.07.006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1715_CR116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1570159X14666151201185652","volume":"14","author":"N Morin","year":"2016","unstructured":"Morin N, Morissette M, Gr\u00e9goire L, Di Paolo T (2016) mGlu5, dopamine D2 and adenosine A2A receptors in l-DOPA-induced dyskinesias. Curr Neuropharmacol 14:481\u2013493","journal-title":"Curr Neuropharmacol"},{"key":"1715_CR117","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bcp.2016.03.023","volume":"109","author":"M Morissette","year":"2016","unstructured":"Morissette M, Morin N, Gr\u00e9goire L et al (2016) Brain \u03b17 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. Biochem Pharmacol 109:62\u201369. doi: 10.1016\/j.bcp.2016.03.023","journal-title":"Biochem Pharmacol"},{"key":"1715_CR118","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/10430340252792486","volume":"13","author":"S-I Muramatsu","year":"2002","unstructured":"Muramatsu S-I, Fujimoto K-I, Ikeguchi K et al (2002) Behavioral recovery in a primate model of Parkinson\u2019s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13:345\u2013354. doi: 10.1089\/10430340252792486","journal-title":"Hum Gene Ther"},{"key":"1715_CR119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ilar.49.1.89","volume":"49","author":"MA Nader","year":"2008","unstructured":"Nader MA, Czoty PW (2008) Brain imaging in nonhuman primates: insights into drug addiction. ILAR J 49:89\u2013102","journal-title":"ILAR J"},{"key":"1715_CR120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","volume":"60","author":"JG Nutt","year":"2003","unstructured":"Nutt JG, Burchiel KJ, Comella CL et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69\u201373","journal-title":"Neurology"},{"key":"1715_CR121","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archneur.58.7.1165","volume":"58","author":"JA Obeso","year":"2001","unstructured":"Obeso JA, Rodriguez MC, Guridi J et al (2001) Lesion of the basal ganglia and surgery for Parkinson disease. Arch Neurol 58:1165\u20131166","journal-title":"Arch Neurol"},{"key":"1715_CR122","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(13)62418-6","volume":"384","author":"JA Obeso","year":"2014","unstructured":"Obeso JA, Rodriguez-Oroz MC, Stamelou M et al (2014) The expanding universe of disorders of the basal ganglia. Lancet 384:523\u2013531. doi: 10.1016\/S0140-6736(13)62418-6","journal-title":"Lancet"},{"key":"1715_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13750","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. doi: 10.1111\/jnc.13750","journal-title":"J Neurochem"},{"key":"1715_CR124","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1212\/WNL.0b013e318199068b","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW (2009) Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 72:S59\u2013S64. doi: 10.1212\/WNL.0b013e318199068b","journal-title":"Neurology"},{"key":"1715_CR125","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1523\/JNEUROSCI.22-12-04942.2002","volume":"22","author":"S Palfi","year":"2002","unstructured":"Palfi S, Leventhal L, Chu Y et al (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22:4942\u20134954","journal-title":"J Neurosci"},{"key":"1715_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-017-0071-y","volume":"6","author":"J Pan","year":"2017","unstructured":"Pan J, Cai H (2017) Opioid system in l-DOPA-induced dyskinesia. Transl Neurodegener 6:1. doi: 10.1186\/s40035-017-0071-y","journal-title":"Transl Neurodegener"},{"key":"1715_CR127","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"1817","unstructured":"Parkinson J (1817) An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 14:223\u2013236","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1715_CR128","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/mds.870100606","volume":"10","author":"RK Pearce","year":"1995","unstructured":"Pearce RK, Jackson M, Smith L et al (1995) Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 10:731\u2013740. doi: 10.1002\/mds.870100606","journal-title":"Mov Disord"},{"key":"1715_CR129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-510X(76)90100-3","volume":"28","author":"JC P\u00e9chadre","year":"1976","unstructured":"P\u00e9chadre JC, Larochelle L, Poirier LJ (1976) Parkinsonian akinesia, rigidity and tremor in the monkey. Histopathological and neuropharmacological study. J Neurol Sci 28:147\u2013157","journal-title":"J Neurol Sci"},{"key":"1715_CR130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.0953-816X.2003.03088.x","volume":"19","author":"M Pessiglione","year":"2004","unstructured":"Pessiglione M, Guehl D, Hirsch EC et al (2004) Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity. Eur J Neurosci 19:426\u2013436","journal-title":"Eur J Neurosci"},{"key":"1715_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2017.02.010","author":"KA Phillips","year":"2017","unstructured":"Phillips KA, Ross CN, Spross J et al (2017) Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus). Behav Brain Res. doi: 10.1016\/j.bbr.2017.02.010","journal-title":"Behav Brain Res"},{"key":"1715_CR132","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1681-3","author":"D Pignataro","year":"2017","unstructured":"Pignataro D, Sucunza D, Rico AJ et al (2017) Gene therapy approaches in the non-human primate model of Parkinson\u2019s disease. J Neural Transm. doi: 10.1007\/s00702-017-1681-3","journal-title":"J Neural Transm"},{"key":"1715_CR133","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/mds.26475","volume":"31","author":"A Pinna","year":"2016","unstructured":"Pinna A, Ko WKD, Costa G et al (2016) Antidyskinetic effect of A2A and 5HT1A\/1B receptor ligands in two animal models of Parkinson\u2019s disease. Mov Disord 31:501\u2013511. doi: 10.1002\/mds.26475","journal-title":"Mov Disord"},{"key":"1715_CR134","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1152\/jn.1960.23.5.534","volume":"23","author":"LJ Poirier","year":"1960","unstructured":"Poirier LJ (1960) Experimental and histological study of midbrain dyskinesias. J Neurophysiol 23:534\u2013551","journal-title":"J Neurophysiol"},{"key":"1715_CR135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0022-510X(74)90083-5","volume":"22","author":"LJ Poirier","year":"1974","unstructured":"Poirier LJ, Lafleur J, de Lean J et al (1974) Physiopathology of the cerebellum in the monkey. 2. Motor disturbances associated with partial and complete destruction of cerebellar structures. J Neurol Sci 22:491\u2013509","journal-title":"J Neurol Sci"},{"key":"1715_CR136","first-page":"175","volume":"149","author":"P Pollak","year":"1993","unstructured":"Pollak P, Benabid AL, Gross C et al (1993) Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (Paris) 149:175\u2013176","journal-title":"Rev Neurol (Paris)"},{"key":"1715_CR137","doi-asserted-by":"publisher","first-page":"e0132368","DOI":"10.1371\/journal.pone.0132368","volume":"10","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer C, Iranzo A, Gaig C et al (2015) Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One 10:e0132368. doi: 10.1371\/journal.pone.0132368","journal-title":"PLoS One"},{"key":"1715_CR138","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/mds.22757","volume":"24","author":"RB Postuma","year":"2009","unstructured":"Postuma RB, Gagnon J-F, Vendette M, Montplaisir JY (2009) Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 24:2225\u20132232. doi: 10.1002\/mds.22757","journal-title":"Mov Disord"},{"key":"1715_CR139","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/ana.24375","volume":"77","author":"LF Potts","year":"2015","unstructured":"Potts LF, Park ES, Woo J-M et al (2015) Dual \u03ba-agonist\/\u03bc-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol 77:930\u2013941. doi: 10.1002\/ana.24375","journal-title":"Ann Neurol"},{"key":"1715_CR140","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5194\/asr-5-11-2010","volume":"5","author":"MJ Prescott","year":"2010","unstructured":"Prescott MJ (2010) Ethics of primate use. Adv Sci Res 5:11\u201322. doi: 10.5194\/asr-5-11-2010","journal-title":"Adv Sci Res"},{"key":"1715_CR141","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mds.25028","volume":"27","author":"M Quik","year":"2012","unstructured":"Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson\u2019s disease. Mov Disord 27:947\u2013957. doi: 10.1002\/mds.25028","journal-title":"Mov Disord"},{"key":"1715_CR142","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A, Dehay B, Bov\u00e9 J et al (2014a) Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75:351\u2013362. doi: 10.1002\/ana.24066","journal-title":"Ann Neurol"},{"key":"1715_CR143","doi-asserted-by":"crossref","unstructured":"Recasens A, Dehay B, Carballo-Carbajal I et al (2014) Lewy body extracts from Parkinson\u2019s disease brain trigger alfa-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 351\u2013362","DOI":"10.1002\/ana.24066"},{"key":"1715_CR144","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","volume":"33","author":"G Riahi","year":"2011","unstructured":"Riahi G, Morissette M, Parent M, Di Paolo T (2011) Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33:1823\u20131831. doi: 10.1111\/j.1460-9568.2011.07675.x","journal-title":"Eur J Neurosci"},{"key":"1715_CR145","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.maturitas.2015.11.009","volume":"84","author":"C Rodr\u00edguez-Nogales","year":"2016","unstructured":"Rodr\u00edguez-Nogales C, Garbayo E, Carmona-Abell\u00e1n MM et al (2016) Brain aging and Parkinson\u2019s disease: new therapeutic approaches using drug delivery systems. Maturitas 84:25\u201331. doi: 10.1016\/j.maturitas.2015.11.009","journal-title":"Maturitas"},{"key":"1715_CR146","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","volume":"8","author":"MC Rodriguez-Oroz","year":"2009","unstructured":"Rodriguez-Oroz MC, Jahanshahi M, Krack P et al (2009) Initial clinical manifestations of Parkinson\u2019s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128\u20131139. doi: 10.1016\/S1474-4422(09)70293-5","journal-title":"Lancet Neurol"},{"key":"1715_CR147","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neurobiolaging.2014.07.017","volume":"36","author":"M Roy","year":"2015","unstructured":"Roy M, Cardoso C, Dorieux O et al (2015) Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. Neurobiol Aging 36:149\u2013156. doi: 10.1016\/j.neurobiolaging.2014.07.017","journal-title":"Neurobiol Aging"},{"key":"1715_CR148","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","volume":"39","author":"D Rylander","year":"2010","unstructured":"Rylander D, Iderberg H, Li Q et al (2010) A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39:352\u2013361. doi: 10.1016\/j.nbd.2010.05.001","journal-title":"Neurobiol Dis"},{"key":"1715_CR149","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0006-8993(90)90108-N","volume":"534","author":"JS Schneider","year":"1990","unstructured":"Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534:25\u201336","journal-title":"Brain Res"},{"key":"1715_CR150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","volume":"519","author":"JS Schneider","year":"1990","unstructured":"Schneider JS, Kovelowski CJ 2nd (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519:122\u2013128","journal-title":"Brain Res"},{"key":"1715_CR151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","volume":"5","author":"A Shimozawa","year":"2017","unstructured":"Shimozawa A, Ono M, Takahara D et al (2017) Propagation of pathological \u03b1-synuclein in marmoset brain. Acta Neuropathol Commun 5:12. doi: 10.1186\/s40478-017-0413-0","journal-title":"Acta Neuropathol Commun"},{"key":"1715_CR152","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839\u2013840","journal-title":"Nature"},{"key":"1715_CR153","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0140-6736(14)60041-6","volume":"384","author":"AJ Stoessl","year":"2014","unstructured":"Stoessl AJ, Lehericy S, Strafella AP (2014) Imaging insights into basal ganglia function, Parkinson\u2019s disease, and dystonia. Lancet 384:532\u2013544. doi: 10.1016\/S0140-6736(14)60041-6","journal-title":"Lancet"},{"key":"1715_CR154","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.26907","volume":"32","author":"AP Strafella","year":"2017","unstructured":"Strafella AP, Bohnen NI, Perlmutter JS et al (2017) Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord 32:181\u2013192. doi: 10.1002\/mds.26907","journal-title":"Mov Disord"},{"key":"1715_CR155","doi-asserted-by":"publisher","unstructured":"Surmeier DJ, Obeso JA, Halliday GM (2017) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18:101\u2013113. doi: 10.1038\/nrn.2016.178","DOI":"10.1038\/nrn.2016.178"},{"key":"1715_CR156","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.neuroscience.2006.04.072","volume":"141","author":"SD Tabbal","year":"2006","unstructured":"Tabbal SD, Mink JW, Antenor JAV et al (2006) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 141:1281\u20131287. doi: 10.1016\/j.neuroscience.2006.04.072","journal-title":"Neuroscience"},{"key":"1715_CR157","doi-asserted-by":"crossref","unstructured":"Taylor JR, Elsworth JD, Roth RH et al (1990) Cognitive and motor deficits in the acquisition of an object retrieval\/detour task in MPTP-treated monkeys. Brain 617\u201337","DOI":"10.1093\/brain\/113.3.617"},{"key":"1715_CR158","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0735-7044.104.4.564","volume":"104","author":"JR Taylor","year":"1990","unstructured":"Taylor JR, Roth RH, Sladek JR, Redmond DE (1990b) Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier. Behav Neurosci 104:564\u2013576","journal-title":"Behav Neurosci"},{"key":"1715_CR159","doi-asserted-by":"publisher","first-page":"e0132064","DOI":"10.1371\/journal.pone.0132064","volume":"10","author":"L Tian","year":"2015","unstructured":"Tian L, Xia Y, Flores HP et al (2015) Neuroimaging analysis of the dopamine basis for apathetic behaviors in an MPTP-lesioned primate model. PLoS One 10:e0132064. doi: 10.1371\/journal.pone.0132064","journal-title":"PLoS One"},{"key":"1715_CR160","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1686-y","author":"O-B Tysnes","year":"2017","unstructured":"Tysnes O-B, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm. doi: 10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm"},{"key":"1715_CR161","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2015.09.028","volume":"766","author":"S Uchida","year":"2015","unstructured":"Uchida S, Soshiroda K, Okita E et al (2015) The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of l-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol 766:25\u201330. doi: 10.1016\/j.ejphar.2015.09.028","journal-title":"Eur J Pharmacol"},{"key":"1715_CR162","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnana.2016.00123","volume":"10","author":"P Vald\u00e9s","year":"2016","unstructured":"Vald\u00e9s P, Schneider BL (2016) Gene therapy: a promising approach for neuroprotection in Parkinson\u2019s disease? Front Neuroanat 10:123. doi: 10.3389\/fnana.2016.00123","journal-title":"Front Neuroanat"},{"key":"1715_CR163","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.expneurol.2015.02.020","volume":"274","author":"R Vanhauwaert","year":"2015","unstructured":"Vanhauwaert R, Verstreken P (2015) Flies with Parkinson\u2019s disease. Exp Neurol 274:42\u201351. doi: 10.1016\/j.expneurol.2015.02.020","journal-title":"Exp Neurol"},{"key":"1715_CR164","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2015.00064","volume":"9","author":"J-M Verdier","year":"2015","unstructured":"Verdier J-M, Acquatella I, Lautier C et al (2015) Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases. Front Neurosci 9:64. doi: 10.3389\/fnins.2015.00064","journal-title":"Front Neurosci"},{"key":"1715_CR165","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.5665\/SLEEP.1174","volume":"34","author":"PS Verhave","year":"2011","unstructured":"Verhave PS, Jongsma MJ, Van den Berg RM et al (2011) REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep 34:1119\u20131125. doi: 10.5665\/SLEEP.1174","journal-title":"Sleep"},{"key":"1715_CR166","doi-asserted-by":"publisher","first-page":"e23952","DOI":"10.1371\/journal.pone.0023952","volume":"6","author":"J Vezoli","year":"2011","unstructured":"Vezoli J, Fifel K, Leviel V et al (2011) Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson\u2019s disease. PLoS One 6:e23952. doi: 10.1371\/journal.pone.0023952","journal-title":"PLoS One"},{"key":"1715_CR167","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/mds.21073","volume":"21","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, Gomez-Ramirez J, Johnston TH et al (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 21:1879\u20131891. doi: 10.1002\/mds.21073","journal-title":"Mov Disord"},{"key":"1715_CR168","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","volume":"39","author":"NP Visanji","year":"2016","unstructured":"Visanji NP, Brotchie JM, Kalia LV et al (2016) \u03b1-Synuclein-based animal models of Parkinson\u2019s disease: challenges and opportunities in a new era. Trends Neurosci 39:750\u2013762. doi: 10.1016\/j.tins.2016.09.003","journal-title":"Trends Neurosci"},{"key":"1715_CR169","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neubiorev.2008.08.006","volume":"33","author":"A Vitale","year":"2009","unstructured":"Vitale A, Manciocco A, Alleva E (2009) The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: the case of Parkinson\u2019s disease. Neurosci Biobehav Rev 33:33\u201347. doi: 10.1016\/j.neubiorev.2008.08.006","journal-title":"Neurosci Biobehav Rev"},{"key":"1715_CR170","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63\u201373. doi: 10.1001\/jama.2008.929","journal-title":"JAMA"},{"key":"1715_CR171","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(98)00669-4","volume":"361","author":"MR Weed","year":"1998","unstructured":"Weed MR, Woolverton WL, Paul IA (1998) Dopamine D1 and D2 receptor selectivities of phenyl-benzazepines in rhesus monkey striata. Eur J Pharmacol 361:129\u2013142","journal-title":"Eur J Pharmacol"},{"key":"1715_CR172","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1037\/1064-1297.15.4.309","volume":"15","author":"EM Weerts","year":"2007","unstructured":"Weerts EM, Fantegrossi WE, Goodwin AK (2007) The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol 15:309\u2013327. doi: 10.1037\/1064-1297.15.4.309","journal-title":"Exp Clin Psychopharmacol"},{"key":"1715_CR173","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, Simuni T, Caspell-Garcia C et al (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov Disord 30:919\u2013927. doi: 10.1002\/mds.26170","journal-title":"Mov Disord"},{"key":"1715_CR174","first-page":"133","volume":"7","author":"JR Whittier","year":"1948","unstructured":"Whittier JR (1948) Rhesus hyperkinesia by subthalamic lesion. Fed Proc 7:133","journal-title":"Fed Proc"},{"key":"1715_CR175","first-page":"226","volume":"6","author":"JR Whittier","year":"1947","unstructured":"Whittier JR, Mettler FA (1947) Subthalamic lesion in the primate. Fed Proc 6:226","journal-title":"Fed Proc"},{"key":"1715_CR200","doi-asserted-by":"crossref","unstructured":"Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 72(2):521\u2013530","DOI":"10.1152\/jn.1994.72.2.521"},{"key":"1715_CR176","doi-asserted-by":"publisher","first-page":"8345","DOI":"10.1523\/JNEUROSCI.0772-15.2015","volume":"35","author":"W Yang","year":"2015","unstructured":"Yang W, Wang G, Wang C-E et al (2015) Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain. J Neurosci 35:8345\u20138358. doi: 10.1523\/JNEUROSCI.0772-15.2015","journal-title":"J Neurosci"},{"key":"1715_CR177","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23917","volume":"27","author":"W Zhan","year":"2012","unstructured":"Zhan W, Kang GA, Glass GA et al (2012) Regional alterations of brain microstructure in Parkinson\u2019s disease using diffusion tensor imaging. Mov Disord 27:90\u201397. doi: 10.1002\/mds.23917","journal-title":"Mov Disord"},{"key":"1715_CR178","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/mds.25817","volume":"29","author":"D Zhang","year":"2014","unstructured":"Zhang D, Bordia T, McGregor M et al (2014a) ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease. Mov Disord 29:508\u2013517. doi: 10.1002\/mds.25817","journal-title":"Mov Disord"},{"key":"1715_CR179","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/jpet.114.216283","volume":"351","author":"D Zhang","year":"2014","unstructured":"Zhang D, McGregor M, Decker MW, Quik M (2014b) The 7 nicotinic receptor agonist ABT-107 decreases l-Dopa-induced dyskinesias in parkinsonian monkeys. J Pharmacol Exp Ther 351:25\u201332. doi: 10.1124\/jpet.114.216283","journal-title":"J Pharmacol Exp Ther"},{"key":"1715_CR180","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.26453","volume":"30","author":"D Zhang","year":"2015","unstructured":"Zhang D, McGregor M, Bordia T et al (2015) \u03b17 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord 30:1901\u20131911. doi: 10.1002\/mds.26453","journal-title":"Mov Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1715-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T09:51:04Z","timestamp":1568973064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1715-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":182,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1715-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]}}}